Three Editorial Board Members of Metabolism and Target Organ Damage Named to the List of Clarivate "Highly Cited Researchers 2022"

Clarivate Analytics revealed the list of "Highly Cited Researchers 2022" on November 15, 2022. Each year, Clarivate™ identifies the world’s most influential researchers ─ the select few who have been most frequently cited by their peers over the last decade. The Editorial Office of Metabolism and Target Organ Damage (M&TOD) are proud to announce that three renowned researchers，Editor-in-Chief Prof. Amedeo Lonardo and Honorary Editors-in-Chief, Prof. Giovanni Targher and Prof. Christopher D. Byrne, are on the list. 

The Editorial Office of M&TOD would like to express sincere and great congratulations to three researchers on "Highly Cited Researchers 2022" designations by Clarivate!

Prof. Amedeo Lonardo
Editor-in-Chief of M&TOD
Highly Cited Researcher in the field of Cross-Field 2022

Operating Unit of Metabolic Syndrome, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy. 

Amedeo Lonardo graduated from the University of Campania "Luigi Vanvitelli" in Italy, where he specialized in Gastroenterology and Digestive Endoscopy. Subsequently, he specialized in Pediatrics and Internal Medicine at the University of Modena and Reggio Emilia. Since April 1988, he has carried out his entire professional career in Modena, first at the Sant'Agostino Hospital, then at the Policlinico and later at the Baggiovara Civil Hospital since its opening. In 2017, Amedeo Lonardo obtained his qualification for National Scientific Qualification in Internal Medicine and Gastroenterology. His main lines of study pertaining to the metabolic pathology of the liver, i.e., the “fatty liver”, which is an indicator but also the cause of cardio-metabolic alterations such as diabetes, hypertension and dyslipidemia. He studied the many clinical manifestations, associations, and complications of fatty liver. Over the past 10 years, he has been ranked in the top 0.012% of scholars studying “fatty liver” worldwide (Expertscape). He was on the board of the scientific journal World Journal of Gastroenterology from 20182021. He was recognized as an exceptional reviewer for Preventing Chronic Disease between January and December 2021. Furthermore, he has been ranked the top reviewer in Clinical Medicine since 2018, according to the Web of Science.

Prof. Giovanni Targher
Honorary Editor-in-Chief of M&TOD
Highly Cited Researcher in the field of Cross-Field 2022

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy.

Giovanni Targher is an Associate Professor of Endocrinology and Diabetology at the University Medical School and Senior Consultant of Endocrinology at the Diabetes and Endocrinology Division, Hospital Trust, Verona, Italy. He received the MD Degree from the University of Verona in 1991 and has been a Board-Certified Specialist in Endocrinology and Diabetology at the University of Verona since 1996. He received several awards or prizes from the Italian Society of Diabetology, the Italian Association of Clinical Endocrinologists, the Italian Society for the Study of Atherosclerosis and the American Association of Clinical Endocrinologists. He currently serves as an Editorial Board member of several reputed scientific journals. He has been ranked in the top 0.003% of scholars in the field of “fatty liver” worldwide over the past 10 years (Expertscape). His major research interest for more than 15 years has been the cause and prevention of nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) using clinical epidemiology and health services translational approaches. He has authored more than 350 peer-reviewed scientific articles and reviews. 

Prof. Christopher D. Byrne
Honorary Editor-in-Chief of M&TOD
Highly Cited Researcher in the field of Cross-Field 2022

Faculty of Medicine, University of Southampton, Southampton, UK.

Christopher D. Byrne was trained as a clinical scientist in the UK and the US, at Cardiff, Cambridge and Stanford Universities and undertook a PhD studying liver lipid metabolism at Cambridge University. After a post-doctoral fellowship at Stanford University and then a Medical Research Council (MRC) fellowship at Cambridge University, he was appointed the Chair of Endocrinology & Metabolism at the University of Southampton in 1999 and was inaugural Director of the Wellcome Trust Clinical Research Facility at Southampton. He is a clinical scientist conducting original research related to metabolic syndrome, obesity and nonalcoholic fatty liver disease (NAFLD). He has been ranked ninth in the world in NAFLD research since 2008 and won the ACCEA Silver award in 2016. He won Banting Memorial Lecture Award 2022 in 2021. He was ranked World Expert and 5th in the world by Expertscape for research in NAFLD (2010-2022) in 2022.

The full list of "2022 Highly Cited Researchers" can be found here: https://clarivate.com/highly-cited-researchers/

Respectfully submitted by Doreen Deng, the Managing Editor of Metabolism and Target Organ Damage